ALB and pancreatic adenocarcinoma: A phase II randomized clinical trial of GEM in combination with HCQ and albumin-bound-paclitaxel in metastasis or advanced pancreatic adenocarcinoma patients have also demonstrated an increased pathologic response rate with the combination [78].